Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 313
- Registration Number
- NCT03384745
- Locations
- 🇵🇱
Investigative Site, Warszawa, Poland
Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2017-11-30
- Target Recruit Count
- 20
- Registration Number
- NCT03358134
- Locations
- 🇳🇱
Academic Medical Center Amsterdam, Amsterdam, Noord-Holland, Netherlands
Molecular Signatures in Inflammatory Skin Disease
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Prof. Dr. Stephan Weidinger
- Target Recruit Count
- 300
- Registration Number
- NCT03358693
- Locations
- 🇩🇪
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT03344640
- Locations
- 🇬🇧
Novartis Investigative Site, Glasgow, United Kingdom
Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Narrows Institute for Biomedical Research
- Target Recruit Count
- 30
- Registration Number
- NCT03307447
- Locations
- 🇺🇸
VA NY Harbor Healthcare System, Brooklyn, New York, United States
Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Diamant Thaci
- Target Recruit Count
- 40
- Registration Number
- NCT03149900
- Locations
- 🇩🇪
University Clinic Schleswig-Holstein, Lubeck, Schleswig-Holstein, Germany
Safety and Efficacy of Secukinumab in Mild Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- James G. Krueger, MD, PhD
- Target Recruit Count
- 23
- Registration Number
- NCT03131570
- Locations
- 🇺🇸
The Rockefeller Univesity, New York, New York, United States
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1048
- Registration Number
- NCT03090100
- Locations
- 🇨🇿
Dermatologicka ambulance, Svitavy, Czechia
🇺🇸Indiana Clinical Trial Center, Plainfield, Indiana, United States
🇺🇸Central Dermatology, Saint Louis, Missouri, United States
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Anne Chang
- Target Recruit Count
- 24
- Registration Number
- NCT03079531
- Locations
- 🇺🇸
Stanford Dermatology, Redwood City, California, United States
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 20
- Registration Number
- NCT03041038
- Locations
- 🇺🇸
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Department of Dermatology Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.